相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms
Samantha N. Champion et al.
MODERN PATHOLOGY (2020)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma
John Timmerman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event
Jennifer Cautela et al.
CANADIAN JOURNAL OF CARDIOLOGY (2020)
T cell checkpoint regulators in the heart
Nir Grabie et al.
CARDIOVASCULAR RESEARCH (2019)
Cardiovascular toxicities associated with immune checkpoint inhibitors
Jiun-Ruey Hu et al.
CARDIOVASCULAR RESEARCH (2019)
Management of Immunotherapy-Related Toxicities. Version 1.2019
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
National Trends, Gender, Management, and Outcomes of Patients Hospitalized for Myocarditis
Zubair Shah et al.
AMERICAN JOURNAL OF CARDIOLOGY (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Myocarditis in the Setting of Cancer Therapeutics Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology
Marc P. Bonaca et al.
CIRCULATION (2019)
Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis
Joe-Elie Salem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Factors Associated With Immune Checkpoint Inhibitor-Related Myocarditis
Yoshito Zamami et al.
JAMA ONCOLOGY (2019)
Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis
Justine L. Newman et al.
CARDIOVASCULAR PATHOLOGY (2019)
Pericardial effusion under nivolumab: case-reports and review of the literature
Anastasia Saade et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer
Yukihiro Toi et al.
JAMA ONCOLOGY (2019)
Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
Sarah Waliany et al.
JACC: CARDIOONCOLOGY (2019)
PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease
Kathryn W. Juchem et al.
JOURNAL OF IMMUNOLOGY (2018)
Vasculitis associated with immune checkpoint inhibitors-a systematic review
Anisha Daxini et al.
CLINICAL RHEUMATOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy
Azadeh Tajmir-Riahi et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S. Mahmood et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Javid J. Moslehi et al.
LANCET (2018)
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Fabio Conforti et al.
LANCET ONCOLOGY (2018)
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients
Matteo Sarocchi et al.
ONCOLOGIST (2018)
Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries
Marion Ferreira et al.
TARGETED ONCOLOGY (2018)
Rebooting Human Immunology
Mark M. Davis et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 36 (2018)
Regulatory Role of CD4+ T Cells in Myocarditis
Daria Vdovenko et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution
Celine Anquetil et al.
CIRCULATION (2018)
A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity
Prabhakaran Kumar et al.
JOURNAL OF AUTOIMMUNITY (2018)
Immune checkpoint inhibitors and cardiovascular toxicity
Alexander R. Lyon et al.
LANCET ONCOLOGY (2018)
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
Mehdi Touat et al.
NEUROLOGY (2018)
MACROPHAGES AND CARDIOVASCULAR HEALTH
Vanessa Frodermann et al.
PHYSIOLOGICAL REVIEWS (2018)
Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells
Cherry S. Leung et al.
GENOME MEDICINE (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
Joe-Elie Salem et al.
LANCET ONCOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Cariad Chester et al.
BLOOD (2018)
Cardiotoxicity with vascular endothelial growth factor inhibitor therapy
Rhian M. Touyz et al.
NPJ PRECISION ONCOLOGY (2018)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2017)
New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma
Juliane Behling et al.
MELANOMA RESEARCH (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Myocardial Infarction Primes Autoreactive T Cells through Activation of Dendritic Cells
Katrien Van der Borght et al.
CELL REPORTS (2017)
Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab
Alexandre Reuben et al.
ONCOIMMUNOLOGY (2017)
Smoldering myocarditis following immune checkpoint blockade
Timothy G. Norwood et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity
Marion Escudier et al.
CIRCULATION (2017)
Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody
Y. Tomita et al.
ANNALS OF ONCOLOGY (2017)
Immune checkpoint dysfunction in large and medium vessel vasculitis
Ryu Watanabe et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2017)
CD28 Costimulation: From Mechanism to Therapy
Jonathan H. Esensten et al.
IMMUNITY (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
Ten years of anti-vascular endothelial growth factor therapy
Napoleone Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cardiovascular Toxic Effects of Targeted Cancer Therapies
Javid J. Moslehi
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
Katrin Klocke et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Lucie Heinzerling et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
CD4+ T Cell Tolerance to Tissue-Restricted Self Antigens Is Mediated by Antigen-Specific Regulatory T Cells Rather Than Deletion
Francois P. Legoux et al.
IMMUNITY (2015)
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies Focus on Kinase Inhibitors
Weijuan Li et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
CTLA-4 and Autoimmunity: New Twists in the Tale
Lucy S. K. Walker
TRENDS IN IMMUNOLOGY (2015)
Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153
Babak Baban et al.
PLOS ONE (2015)
LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
Feng Xu et al.
CANCER RESEARCH (2014)
Gender differences in myocarditis: a nationwide study in Finland
V. Kyto et al.
EUROPEAN HEART JOURNAL (2014)
The heart of the matter: Protection of the myocardium from T cells
Andrew H. Lichtman
JOURNAL OF AUTOIMMUNITY (2013)
Role of the PD-1 Pathway in the Immune Response
L. V. Riella et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?
Ronald M. Witteles et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Tadashi Yokosuka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis
Margarite L. Tarrio et al.
JOURNAL OF IMMUNOLOGY (2012)
Myocardial Infarction Triggers Chronic Cardiac Autoimmunity in Type 1 Diabetes
R. V. S. R. K. Gottumukkala et al.
Science Translational Medicine (2012)
Impaired thymic tolerance to α-myosin directs autoimmunity to the heart in mice and humans
HuiJuan Lv et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
Taku Okazaki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
PD-1 deficiency results in the development of fatal myocarditis in MRL mice
Jian Wang et al.
INTERNATIONAL IMMUNOLOGY (2010)
CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms
Wataru Ise et al.
NATURE IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Genetic Evidence That the Differential Expression of the Ligand-Independent Isoform of CTLA-4 Is the Molecular Basis of the Idd5.1 Type 1 Diabetes Region in Nonobese Diabetic Mice
Manabu Araki et al.
JOURNAL OF IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice
Julie A. Lucas et al.
JOURNAL OF IMMUNOLOGY (2008)
Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell-mediated injury in the heart
Nir Grabie et al.
CIRCULATION (2007)
CTLA-4 ablation and interleukin-12-driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes
Victoria A. Love et al.
CIRCULATION RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium
Stefan Goeser et al.
CIRCULATION (2006)
Colchicine in addition to conventional therapy for acute pericarditis - Results of the colchicine for acute pericarditis (COPE) trial
M Imazio et al.
CIRCULATION (2005)
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells
YE Latchman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo
CJ Workman et al.
JOURNAL OF IMMUNOLOGY (2004)
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice
T Okazaki et al.
NATURE MEDICINE (2003)
Endothelial expression of PD-L1 and PD-L2 down-regulates CD8(+) T cell activation and cytolysis
N Rodig et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney et al.
NATURE (2002)
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength
JG Egen et al.
IMMUNITY (2002)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
分享论文
